Back to search results

Improving HPV Vaccination Rates in Latino/a Adolescents

This study is looking at ways to increase Human Papillomavirus (HPV) vaccination rates among Latino/a adolescents aged 11 to 17. Researchers are testing different strategies, led by a facilitator, within Federally Qualified Health Centers (FQHCs). These strategies aim to help healthcare providers recommend the HPV vaccine more often and improve vaccination rates in their clinics. The study will measure success by looking at the percentage of eligible adolescents who receive their first and second doses of the HPV vaccine before their 13th birthday. The study is currently unclear on its recruitment status and plans to enroll 225 participants.

Study design
This is an interventional study that will involve 225 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from baseline to the end of the study, which is about 60 months from baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06598475

Investigating Facilitator-driven, Multi-level Implementation Strategies in Federally Qualified Health Centers to Improve Provider Recommendation and HPV Vaccination Rates Among Latino/a Adolescents

Recruiting
NAAges 11–17InterventionalPrevention
The University of Texas Health Science Center, Houston
~225 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Facilitator-driven provider- and practice-level implementation strategies for influencing provider recommendations and practice-level HPV vaccination rates

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of vaccine-eligible males and females at each clinic who received the first valid dose of the HPV vaccine series before their 13th birthday.
Measured over From baseline to end of study ( about 60 months from baseline)
+1 more outcome measured

Conditions

Human Papillomavirus Infection

Explore related trials

Human Papillomavirus Infection

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Daisy Y Morales Campos, PhD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Daisy Y Morales-Campos, PhD
[email protected]
(210) 276 9042
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

FQHC's with less than 60% HPV vaccine initiation rate for 11-12 year old adolescents overall at their practice sites
FQHC's that have family medicine and/or pediatric practices
a total adolescent patient population at least 50% Latino
be willing for Health Care Provider (HCP) and staff members to receive education, training, and support; complete standardized measurement, and agree to randomization.
Providers, aged 18 and over, employed at each FQHC (4 staff per practice)
Staff, aged 18 and over, employed at each FQHC (5 staff per practice)
Implementation team members (i.e., administrative designee, health care providers, immunization navigators, and other staff), aged 18 and over, employed at each FQHC (4 members per practice)
Parents (aged 18 and over) of patients ages 11-17 seeking care at each FQHC (25 per practice).

Exclusion

FQHCs that participated in the pilot study were excluded.

What this trial measures

  • Percentage of vaccine-eligible males and females at each clinic who received the first valid dose of the HPV vaccine series before their 13th birthday.From baseline to end of study ( about 60 months from baseline)
  • Percentage of vaccine-eligible males and females at each clinic who received the second valid dose of the HPV vaccine series 6-12 months after their first dose and before their 13th birthday.From baseline to end of study ( about 60 months from baseline)